NAV
$41.52
AUM
$16.6B
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.91
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +10.12% | +2.80% | +6.11% | +22.31% | +18.01% | +10.07% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ASML | ASML Holding NV ADR | 1.57% |
| 2 | HSBA.L | HSBC Holdings PLC | 1.05% |
| 3 | ROP.SW | Roche Holding AG Ordinary Shares new | 1.00% |
| 4 | SHEL.L | Shell PLC | 0.95% |
| 5 | AZN.L | AstraZeneca PLC | 0.91% |
| 6 | NESN.SW | Nestle SA | 0.86% |
| 7 | 8306.T | Mitsubishi UFJ Financial Group Inc | 0.68% |
| 8 | NVS | Novartis AG ADR | 0.64% |
| 9 | BHP.AX | BHP Group Ltd | 0.64% |
The fund will invest in companies of all sizes, with increased exposure to smaller capitalization, lower relative price, and higher profitability companies as compared to their representation in the International Universe. As a non-fundamental policy, under normal circumstances, it will invest at least 80% of its net assets in equity securities. The Advisor may also increase or reduce the fund's exposure to an eligible company, or exclude a company, based on shorter-term considerations, such as a company's price momentum, short-run reversals, and investment characteristics.
Inception Date: 2020-11-17